Product Images Bortezomib

This appears to be a graph showing the number of patients over time and their response to two different treatments, "VCR.CAP" and "RCHOP". The treatments may be related to cancer therapy, as "R-CHOP" is a standard chemotherapy regimen used to treat some lymphomas. However, without additional context, it is not possible to determine the specific conditions or outcomes being measured.*

This appears to be a partial result from a clinical trial comparing two treatments, with data on patient survival ("subjects alive"), a hazard ratio, and a chart showing patient outcomes over time for both treatments ("VeR-CAP" and "R-CHOP"). However, without further context or additional information, it is not possible to provide a more specific or useful description.*

This is a product description for a medication called Bortezomib for Injection, used for intravenous or subcutaneous use. Each vial contains 3.5 mg of bortezomib and 35 mg of mar. The usual dosage varies and should be found on the accompanying packaging. Storage should be at 25°C, and unused portions should be discarded. There are specific excursions permitted for temperature, as specified. Natural materials were not used in the manufacturing of the container closure. The medication is manufactured by Zys Hospira Oncology Pt Ltd in Anmedehad, I, and distributed by Zycus Phamaceuticals (USA) Inc. in Penringon, NJ. Code No: G DRUBSIGIZA26T.*

This is a medication instruction for Bortezomib, which comes in the form of an injection for intravenous or subcutaneous use. Each vial contains 3.5 mg/vial of reconstituted Bortezomib. The medication should be stored between 15°C to 30°C and should be protected from light. The manufacturer is Zydus Pharmaceuticals and the medication is only available with a prescription. Details on reconstitution can be found on page 2 of the package insert.*